Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Gilead Sciences, retaining the price target of $135.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Evan Seigerman has given his Buy rating due to a combination of factors that highlight Gilead Sciences’ promising future in the HIV treatment market. The company’s recent ARTISTRY-1 trial data indicates that the single-dose combination of bictegravir and lenacapavir is as effective as existing multi-pill regimens for virologically suppressed HIV patients. This development suggests a significant improvement in patient adherence and experience, particularly for those with complex treatment needs, thereby strengthening Gilead’s position in the HIV market.
Furthermore, Gilead’s current leading treatment, Biktarvy, has its exclusivity extended until 2036, ensuring continued revenue from its HIV franchise. The potential launch of Bic/Len as early as 2027, pending further trial results, could further enhance Gilead’s market dominance. Additionally, Gilead’s efforts in oncology, particularly with Trodelvy and Cell, are expected to be the next growth drivers, providing a robust outlook for the company’s future performance. These factors combined make Gilead Sciences an attractive investment opportunity, justifying the Buy rating.
Seigerman covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Vertex Pharmaceuticals, and Pfizer. According to TipRanks, Seigerman has an average return of 5.4% and a 48.97% success rate on recommended stocks.
In another report released today, Citi also maintained a Buy rating on the stock with a $135.00 price target.